who should not use glp-1 Why I'm Choosing to Take GLP-1s, Even Though Everyone Expects Me To Compounded GLP-1 medications are trending

The last assessment occurred at week 10 and included the same assessments as per baseline

On paper, CagriSema produced a marginally higher percentage in slightly less time

In published clinical trials, once weekly cagrilintide has been reported to produce dose dependent body weight reductions in participants with overweight or obesity, and it has also been studied in combination programmes with semaglutide, where trials reported greater weight loss than either component alone

Some employers have begun to include obesity medications as part of wellness initiatives, recognizing their potential to reduce long-term healthcare costs